Company Profiles

driven by the PitchBook Platform

Kolltan Pharmaceuticals

Kolltan Pharmaceuticals
2007 FOUNDED
M&A STATUS
41-50 EMPLOYEES
M&A LATEST DEAL TYPE
$235M LATEST DEAL AMOUNT
Description

Developer of monoclonal antibody drugs. The company is a clinical-stage enterprise focused on discovery and development of drug candidates targeting receptor tyrosine kinases (RTKs) that impact oncology and immunology. The company's most advanced product candidates include KTN3379, a monoclonal antibody drug candidate targeting ErbB3 (HER3), which is currently in clinical development for the potential treatment of different solid tumors, and KTN0158, a monoclonal antibody targeting KIT, which is in clinical evaluation for cancer and preclinical evaluation for mast cell diseases.

Website
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Primary Office
300 George Street
Suite 530
New Haven, CT 06511
United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Kolltan Pharmaceuticals’s full profile, request a free trial.

Kolltan Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 29-Nov-2016 $235M 00000 00000 Completed Clinical Trials - Phase 1
6. IPO 28-Jan-2015 000.00 Cancelled Clinical Trials - Phase 1
5. Later Stage VC (Series D) 17-Mar-2014 0000 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series C) 07-Mar-2012 0000 0000 00000 Completed Startup
3. Early Stage VC (Series B) 20-Jan-2010 0000 0000 000.00 Completed Startup
2. Grant 31-Dec-2009 $240K $40M Completed Startup
1. Early Stage VC (Series A) 18-Aug-2009 $40M $40M 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Kolltan Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 00,000,000 00.000000 00.00 00 00 00 00 00.000
Series C 00,000,000 00.000000 00.00 00 00 00 00 00.000
Series B 10,000,000 $0.001000 $0.04 $1.1 $1.1 1x $1.1 6.29%
Series A 40,000,000 $0.001000 $1 $1 1x $1 27.66%
To view this company’s complete Cap Table, request access »

Kolltan Pharmaceuticals Investments & Acquisitions (1)

Company Name Date Type Deal Size Industry Lead Partner
0000000 0000000000 07-Aug-2014 000000000000000000 Other Commercial Services 000000 000000000000 00.0
To view this company’s complete investment and acquisition history, request access »

Kolltan Pharmaceuticals Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Auven Therapeutics PE/Buyout Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Elm Street Ventures PE/Buyout Minority 000 0000 000000 0
Fidelity Investments Mutual Fund Minority 000 0000 000000 0
Gilead Sciences PE-Backed Company Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

Kolltan Pharmaceuticals Executive Team (13)

Name Title Board
Seat
Contact
Info
Joseph Schlessinger Ph.D Co-Founder, Director and Chairman of Scientific Advisory Board
Lisa Kamen Director, Clinical Operations
Leigh Feigenbaum Director, Regulatory & Clinical Affairs
Colin Callaghan Senior Director, Product Development & Product Management
Ronald Peck MD Co-Chief Medical Officer & Senior Vice President of Clinical Development

5 Former Executives

You’re viewing 5 of 13 executives. Get the full list »

Kolltan Pharmaceuticals Board Members (9)

Name Representing Role Since Contact
Info
Arthur Altschul Jr. Self Co-Founder and Chairman 000 0000
Daniel Vlock MD Self Director 000 0000
Frank Karbe Kolltan Pharmaceuticals Board Member 000 0000
Jonathan Soderstrom Ph.D Self Director 000 0000
K. Peter Hirth Ph.D Self Director 000 0000

2 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »
Questions or concerns about this profile? Reach out to website-support@pitchbook.com